| Here's Why Insulet (PODD) is a Strong Momentum Stock |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-05-16 14:56:33 |
Czytaj oryginał (ang.) |
| Why Insulet (PODD) is a Top Growth Stock for the Long-Term |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-05-15 14:50:20 |
Czytaj oryginał (ang.) |
| Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer |
Insulet Corporation's NASDAQ: PODD recent outperformance has caught investors' attention and has earned it a designation as a top performer on the S&P 500. |
marketbeat.com |
2025-05-14 12:46:41 |
Czytaj oryginał (ang.) |
| Outlier Money Flows Lift Insulet |
Big Money buying shares of Insulet Corporation (PODD). |
fxempire.com |
2025-05-14 11:20:10 |
Czytaj oryginał (ang.) |
| Insulet Announces Publication of 2024 Sustainability Report |
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, is proud to announce the publication of its 2024 Sustainability Report. This report underscores Insulet's unwavering commitment to sustainable practices and highlights significant achievements in environmental, social, and governance (ESG) initiatives. “At Insulet, our sustainability impact is inextricably tied to. |
businesswire.com |
2025-05-13 10:00:00 |
Czytaj oryginał (ang.) |
| Insulet Q1 Earnings Top Estimates, Stock Up, 2025 Sales View Raised |
PODD delivers better-than-expected earnings and revenues in the first quarter of 2025. |
zacks.com |
2025-05-12 14:10:49 |
Czytaj oryginał (ang.) |
| S&P 500 Giants Visa, Insulet Lead 5 Stocks Near Buy Points |
Visa has topped a buy point, while fellow S&P 500 component Insulet gapped out of a base, leading five stocks on this weekend watchlist. |
investors.com |
2025-05-10 15:47:52 |
Czytaj oryginał (ang.) |
| S&P 500 Gains & Losses Today: Index Pulls Back Early Climb Amid Anticipation of Trade Talks |
Major U.S. equities indexes pulled back from their early gains Friday as investors wait for new developments on tariffs ahead of a weekend meeting between U.S. and Chinese officials. |
investopedia.com |
2025-05-09 22:31:34 |
Czytaj oryginał (ang.) |
| Insulet Stock Soars To A High After Robust Earnings; This Customer Management Name Pops |
Insulet stock soared after the company topped first quarter earnings and sales estimates. And a customer management stock hit a new high. |
investors.com |
2025-05-09 20:02:47 |
Czytaj oryginał (ang.) |
| Top Stock Movers Now: Tesla, Monster Beverage, Insulet, and More |
U.S. equities were mixed and little changed at midday as the markets awaited key trade talks between the U.S. and China set for this weekend. The Dow Jones Industrial Average edged lower, while the S&P 500 and Nasdaq were slightly higher. |
investopedia.com |
2025-05-09 16:31:23 |
Czytaj oryginał (ang.) |
| Insulet Posts Strong Q1 Results, Raises Forecasts On Momentum In US And Abroad |
Insulet Corporation PODD reported first-quarter adjusted earnings of $1.02 per share, beating the consensus of 80 cents. |
benzinga.com |
2025-05-09 15:05:57 |
Czytaj oryginał (ang.) |
| Insulet Is the Top S&P 500 Performer Today. Here's Why. |
The insulin pump maker beat earnings expectations for the first quarter and raised its forecast for 2025. |
barrons.com |
2025-05-09 14:11:00 |
Czytaj oryginał (ang.) |
| Insulet Corporation (PODD) Q1 2025 Earnings Call Transcript |
Insulet Corporation (NASDAQ:PODD ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants June Lazaroff - Senior Director, IR Tim Scannell - Chair Ashley McEvoy - President and CEO Ana Chadwick - EVP and CFO Eric Benjamin - Chief Product and Customer Experience Officer Conference Call Participants Travis Steve - Bank of America Robbie Marcus - JPMorgan Jeff Johnson - Baird Larry Biegelsen - Wells Fargo Joanne Wuensch - Citi Patrick Wood - Morgan Stanley Marie Thibault - BTIG Michael Polark - Wolfe Research Matt O'Brien - Piper Sandler Steve Lichtman - Oppenheimer Issie Kirby - Redburn Atlantic Operator Good afternoon, ladies and gentlemen, and welcome to the Insulet Corporation First Quarter Earnings Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-05-09 02:35:20 |
Czytaj oryginał (ang.) |
| Insulet (PODD) Reports Q1 Earnings: What Key Metrics Have to Say |
Although the revenue and EPS for Insulet (PODD) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-05-08 22:31:12 |
Czytaj oryginał (ang.) |
| Insulet (PODD) Q1 Earnings and Revenues Surpass Estimates |
Insulet (PODD) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.73 per share a year ago. |
zacks.com |
2025-05-08 22:20:43 |
Czytaj oryginał (ang.) |
| Insulet beats quarterly profit estimates on insulin pump demand |
Insulet beat first-quarter profit estimates on Thursday, buoyed by strong demand for its wearable insulin pumps, sending shares up 7% in extended trading. |
reuters.com |
2025-05-08 20:28:43 |
Czytaj oryginał (ang.) |
| Curious about Insulet (PODD) Q1 Performance? Explore Wall Street Estimates for Key Metrics |
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Insulet (PODD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025. |
zacks.com |
2025-05-05 14:22:10 |
Czytaj oryginał (ang.) |
| Insulet Names New CEO, Expects to Top Revenue Projections |
Insulet (PODD) shares edged lower Monday as the maker of an insulin delivery device for diabetes patients announced a shakeup in its leadership. |
investopedia.com |
2025-04-28 14:26:04 |
Czytaj oryginał (ang.) |
| Insulet Appoints Ashley McEvoy President and CEO |
ACTON, Mass.--(BUSINESS WIRE)--Insulet Appoints Ashley McEvoy President and CEO. |
businesswire.com |
2025-04-28 10:00:00 |
Czytaj oryginał (ang.) |
| 4 Medical Product Stocks to Buy From a Challenging Industry |
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR are likely to gain from the favorable factors. |
zacks.com |
2025-04-17 13:55:37 |
Czytaj oryginał (ang.) |
| Insulet Sales Keep Rising |
Insulet Corporation (PODD) continues its strong sales and growth trend. |
fxempire.com |
2025-02-26 10:04:14 |
Czytaj oryginał (ang.) |
| Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst |
On Thursday, Insulet Corporation PODD reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the consensus of $1.02. |
benzinga.com |
2025-02-21 15:28:14 |
Czytaj oryginał (ang.) |
| PODD Stock Falls Despite Q4 Earnings and Revenue Beat, Margins Rise |
Insulet's fourth-quarter results benefit from the continued high demand for Omnipod 5. |
zacks.com |
2025-02-21 11:40:32 |
Czytaj oryginał (ang.) |
| Insulet Corporation (PODD) Q4 2024 Earnings Call Transcript |
Insulet Corporation (NASDAQ:PODD ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants June Lazaroff - Senior Director of Investor Relations Jim Hollingshead - President & Chief Executive Officer Ana Chadwick - Executive Vice President, Chief Financial Officer & Treasurer Conference Call Participants Robert Marcus - JPMorgan Jeffrey Johnson - Baird Travis Steed - Bank of America Michael Polark - Wolfe Research Issie Kirby - Redburn Atlantic Patrick Wood - Morgan Stanley Macauley Kilbane - William Blair Larry Biegelsen - Wells Fargo Marie Thibault - BTIG Mike Kratky - Leerink Partners Jayson Bedford - Raymond James Matt Taylor - Jefferies Phillip Dantoin - Piper Sandler Chris Pasquale - Nephron Research Joanne Wuensch - Citi Operator Good afternoon ladies and gentlemen and welcome to the Insulet Corporation Fourth Quarter and Full Year 2024 Earnings Call. At this time all participants are in a listen-only mode. |
seekingalpha.com |
2025-02-21 01:37:03 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Insulet (PODD) Q4 Earnings: A Look at Key Metrics |
While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-02-20 20:30:33 |
Czytaj oryginał (ang.) |
| Insulet (PODD) Q4 Earnings and Revenues Top Estimates |
Insulet (PODD) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $1.40 per share a year ago. |
zacks.com |
2025-02-20 20:15:24 |
Czytaj oryginał (ang.) |
| Insulet beats quarterly profit estimates on insulin pump demand |
Insulet reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps. |
reuters.com |
2025-02-20 18:55:22 |
Czytaj oryginał (ang.) |
| Insulet Reports Full Year 2024 Revenue Increase of 22% and Fourth Quarter 2024 Revenue Increase of 17% Year-Over-Year |
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months and full year ended December 31, 2024. "We concluded an incredible year with a very strong fourth quarter, achieving significant milestones across the business, and exceeding our growth and margin objectives," said Jim Hollingshead, Insulet President and Chief. |
businesswire.com |
2025-02-20 18:01:00 |
Czytaj oryginał (ang.) |
| Stay Ahead of the Game With Insulet (PODD) Q4 Earnings: Wall Street's Insights on Key Metrics |
Beyond analysts' top -and-bottom-line estimates for Insulet (PODD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024. |
zacks.com |
2025-02-14 12:21:17 |
Czytaj oryginał (ang.) |
| NVIDIA & 2 Other Profitable Stocks to Buy in February |
NVIDIA, AppLovin and Insulet have been selected as the top picks with a high net income ratio. |
zacks.com |
2025-01-31 18:05:15 |
Czytaj oryginał (ang.) |
| Here's Why You Should Add PODD Stock to Your Portfolio Now |
Insulet stays on investors' radar owing to its solid progress with Omnipod 5 and strong solvency position. |
zacks.com |
2025-01-30 09:11:08 |
Czytaj oryginał (ang.) |
| GEHC or PODD: Which Is the Better Value Stock Right Now? |
Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and Insulet (PODD). But which of these two stocks is more attractive to value investors? |
zacks.com |
2025-01-16 14:41:13 |
Czytaj oryginał (ang.) |
| PODD Stock Gains From the Launch of Omnipod 5 in Five Countries in EU |
Insulet announces the launch of Omnipod 5 in five more countries in Europe, Italy, Denmark, Finland, Norway and Sweden. |
zacks.com |
2025-01-14 10:56:34 |
Czytaj oryginał (ang.) |
| Insulet Launches Revolutionary Omnipod® 5 in Five More Countries in Europe |
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the Omnipod 5 Automated Insulin Delivery System is now commercially available in five more countries—Italy, Denmark, Finland, Norway, and Sweden. Omnipod 5 is now available with both Abbott's FreeStyle Libre 2 Plus and Dexcom G6 Continuous Glucose Monitoring (CGM) sensor compatibility. Indicated for. |
businesswire.com |
2025-01-13 18:01:00 |
Czytaj oryginał (ang.) |
| Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025 |
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the fourth quarter and full year of 2024 on February 20, 2025, after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available. |
businesswire.com |
2025-01-10 08:00:00 |
Czytaj oryginał (ang.) |
| GEHC vs. PODD: Which Stock Is the Better Value Option? |
Investors interested in stocks from the Medical - Products sector have probably already heard of GE HealthCare Technologies (GEHC) and Insulet (PODD). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2024-12-31 14:41:11 |
Czytaj oryginał (ang.) |
| Heavy Interest in Insulet's Insulin Delivery Device |
Sales are surging for Insulet Corporation (PODD). |
fxempire.com |
2024-12-27 17:47:51 |
Czytaj oryginał (ang.) |
| Why Insulet (PODD) is a Top Momentum Stock for the Long-Term |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-12-13 12:56:27 |
Czytaj oryginał (ang.) |
| RMD or PODD: Which Is the Better Value Stock Right Now? |
Investors interested in Medical - Products stocks are likely familiar with ResMed (RMD) and Insulet (PODD). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2024-12-12 14:41:20 |
Czytaj oryginał (ang.) |
| Should You Continue to Retain Insulet Stock in Your Portfolio Now? |
PODD stock stays on investors' radar owing to its solid progress with Omnipod 5 and robust potential in the diabetes market. |
zacks.com |
2024-12-09 10:26:10 |
Czytaj oryginał (ang.) |
| Insulet wins $452 mln US verdict against EOFlow in insulin pump secrets case |
Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade secrets related to insulin pumps, according to a verdict made public in Massachusetts federal court on Thursday. |
reuters.com |
2024-12-05 13:05:42 |
Czytaj oryginał (ang.) |
| Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court |
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced that it has successfully defended its intellectual property against EOFlow Co., Ltd. (“EOFlow") in federal court. After a four-week trial in the U.S. District Court for the District of Massachusetts in the matter of Insulet Corporation vs. EOFlow et al., a jury verdict was returned in favor of Insulet on. |
businesswire.com |
2024-12-04 18:28:00 |
Czytaj oryginał (ang.) |
| Here's Why Insulet (PODD) is a Strong Growth Stock |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2024-11-29 12:50:17 |
Czytaj oryginał (ang.) |
| PODD Stock to Gain From Launch of Omnipod 5 With Abbott's CGM in US |
Insulet's Omnipod 5 System is now compatible with Abbott's FreeStyle Libre 2 Plus Sensor in the United States. |
zacks.com |
2024-11-22 13:15:16 |
Czytaj oryginał (ang.) |
| Insulet Corporation: Significant Opportunities, Significant Threats - I'm On The Sidelines |
Insulet's stock has surged over 50% in six months due to strong Q3 earnings and expanded market potential with Omnipod 5's approval for Type 2 diabetes. Despite impressive growth, high market expectations and potential competition from giants like Medtronic and Abbott pose significant risks to Insulet's future performance. The company's financials are robust, with rising revenues, margins, and a strong cash position, but the stock's high valuation demands continued exceptional growth. |
seekingalpha.com |
2024-11-20 20:26:08 |
Czytaj oryginał (ang.) |
| Insulet Announces Omnipod® 5 System is Now Compatible with Abbott's FreeStyle Libre 2 Plus Sensor in the U.S. |
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the Omnipod 5 Automated Insulin Delivery (AID) System is now compatible with Abbott's FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor in the U.S. This makes Omnipod 5 the most connected tubeless AID system in the U.S. “We are excited to announce that Omnipod 5, the only AID system. |
businesswire.com |
2024-11-20 10:30:00 |
Czytaj oryginał (ang.) |
| Insulet to Present at Upcoming Investor Conferences |
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at three upcoming investor conferences (all Eastern Time): The 6th Annual Wolfe Research Healthcare Conference in New York City on Wednesday, November 20, 2024 at 12:00 p.m. The Nasdaq 51st Investor Conference in London on Tuesday, December 10, 2024 at 5:30 a.m. The J.P. Morgan 43rd An. |
businesswire.com |
2024-11-15 08:00:00 |
Czytaj oryginał (ang.) |
| Buy Profitable S&P 500 Stocks as the Index Tops 6000: NVIDIA & 2 More |
NVIDIA, Insulet and Howmet Aerospace have been selected as the top picks with a high net income ratio. |
zacks.com |
2024-11-12 18:06:11 |
Czytaj oryginał (ang.) |
| Why Insulet (PODD) is a Top Growth Stock for the Long-Term |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2024-11-12 12:51:30 |
Czytaj oryginał (ang.) |
| PODD Stock Gains on Q3 Earnings and Revenue Beat, '24 Sales View Up |
Insulet's third-quarter performance benefits from the continued high demand for Omnipod 5. |
zacks.com |
2024-11-12 11:10:44 |
Czytaj oryginał (ang.) |
| Insulet CEO on earnings, GLP-1 and election impact |
Jim Hollingshead, Insulet CEO, joins 'Closing Bell: Overtime' to discuss the Insulet earnings, Apple blood sugar testing app and more. |
youtube.com |
2024-11-11 18:59:04 |
Czytaj oryginał (ang.) |
| Buy, Sell, Or Hold Insulet (PODD) Stock? |
Insulet stock (NASDAQ: PODD) surged nearly 10% on Friday, November 8, after the company posted an upbeat Q3 and raised its sales outlook. It reported sales of $544 million and adjusted earnings of $0.90 per share, compared to the consensus estimates of $518 million and $0.77, respectively. |
forbes.com |
2024-11-11 11:42:46 |
Czytaj oryginał (ang.) |
| Insulet Corporation (PODD) Q3 2024 Earnings Call Transcript |
Insulet Corporation (PODD) Q3 2024 Earnings Call Transcript |
seekingalpha.com |
2024-11-08 00:54:39 |
Czytaj oryginał (ang.) |
| Insulet (PODD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates |
Although the revenue and EPS for Insulet (PODD) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2024-11-07 20:30:38 |
Czytaj oryginał (ang.) |
| Insulet (PODD) Q3 Earnings and Revenues Top Estimates |
Insulet (PODD) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to earnings of $0.71 per share a year ago. |
zacks.com |
2024-11-07 20:21:14 |
Czytaj oryginał (ang.) |